Literature DB >> 14600688

Treatment of perioral dystonia with botulinum toxin in 4 cases of Meige's syndrome.

Eigild Møller1, Lene M Werdelin, Merete Bakke, Torben Dalager, Svend Prytz, Lisbeth Regeur.   

Abstract

OBJECTIVE: We describe the treatment of 4 patients (median age, 53.5 years) with incapacitating perioral dystonia and insufficient response to peroral medication. Their general treatment with clonazepam and anticholinergics was supplemented by intramuscular injections with botulinum toxin A (20-40 U) in the orbicularis oris muscle, guided by electromyography (EMG). STUDY
DESIGN: Perioral dystonia and treatment effect were assessed by using subjective global and visual analog scales, examiner-based video movement counts and rating scales, and quantitative EMG. t Tests were used for statistical analysis.
RESULTS: The result of the intramuscular botulinum toxin A injections was characterized by the patients as "much improved"; correspondingly, dystonia was significantly reduced in visual analog scale scores, on examiner-based assessments, and in recordings of EMG. The side effects were few and short-lasting.
CONCLUSION: Incapacitating perioral dystonia in Meige's syndrome may be safely controlled by recurrent EMG-guided botulinum toxin A injections in the orbicularis oris muscle, in combination with general medication.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14600688     DOI: 10.1016/j.tripleo.2003.08.011

Source DB:  PubMed          Journal:  Oral Surg Oral Med Oral Pathol Oral Radiol Endod        ISSN: 1079-2104


  2 in total

Review 1.  Meige syndrome: what's in a name?

Authors:  Mark S LeDoux
Journal:  Parkinsonism Relat Disord       Date:  2009-05-19       Impact factor: 4.891

2.  Application of electrophysiological methods and magnetic resonance tomographic angiography in the differentiation between hemifacial spasm and Meige syndrome.

Authors:  Chuyi Huang; Suhua Miao; Heling Chu; Aikeremujiang Muheremu; Jinting Wu; Rongsong Zhou; Huancong Zuo; Yu Ma
Journal:  Neurol Sci       Date:  2016-02-02       Impact factor: 3.307

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.